EURONEXT-PAR$ABVX
Abivax SA · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Abivax SA reported Q1 2026 financial results on May 22, 2026, showing increased operating expenses and a net loss of €48.5 million.
Abivax SA, a clinical-stage biotech, reported its Q1 2026 results (three months ended March 31, 2026) with total operating income of €1.3 million and operating expenses of €57.6 million, leading to an operating loss of €56.2 million. The company had cash, cash equivalents, and short-term investments of €491.6 million, providing runway into Q4 2027. Net loss was €48.5 million or approximately €0.61 per share.
- Cash position of €491.6 million as of March 31, 2026, with runway into Q4 2027.
- R&D expenses increased to €49.5 million from €39.3 million year-over-year.
- Operating loss widened to €56.2 million from €47.2 million in Q1 2025.
- Financial gain of €8.0 million helped reduce net loss to €48.5 million.
Headline financials
Revenue & EPS history
Abivax SA · Revenue · Quarterly
€0
Forward guidance
Cash runway projected into Q4 2027; upcoming milestones include H1 2026 results on Sept 21, 2026, and NDA submission in Q4 2026.
Tailwinds
- Strong cash position supporting operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports
+0.7%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+16.9%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+1.5%
Q2 2025
Best reaction
-0.2%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q2 2025 | +1.5% | -6.7% | +0.7% | |
| Q1 2025 | -0.2% | +11.6% | +30.1% | |
| Q4 2023 | +0.9% | +0.4% | +20.1% | |
| Q2 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro